stockportfolio.pro
Start 7-day free trial
DexCom, Inc. (DXCM)
Healthcare · Medical Devices · NasdaqGS
DexCom, Inc. revenue & earnings (annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $4.66B | $4.03B | $3.62B | $2.91B |
| Gross profit | $0 | $0 | $0 | $0 |
| Net income | $836.30M | $576.20M | $541.50M | $341.20M |
See the full financials for DexCom, Inc.
Full income statement, balance sheet and cash flow (28+ line items across multiple years), an interactive price & market-cap chart, valuation ratios, and the ability to track DXCM in your own portfolio.
Start your 7-day free trialAbout DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.